MetLife Investment Management LLC Purchases 38,400 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

MetLife Investment Management LLC raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 133,425 shares of the company's stock after purchasing an additional 38,400 shares during the quarter. MetLife Investment Management LLC's holdings in Teva Pharmaceutical Industries were worth $2,941,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Robeco Institutional Asset Management B.V. boosted its position in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock valued at $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP bought a new stake in Teva Pharmaceutical Industries during the 4th quarter worth $4,966,000. Asset Management One Co. Ltd. grew its position in Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after acquiring an additional 58,413 shares during the last quarter. CWA Asset Management Group LLC acquired a new position in Teva Pharmaceutical Industries in the 4th quarter worth about $3,340,000. Finally, Allspring Global Investments Holdings LLC raised its position in Teva Pharmaceutical Industries by 2,018.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock valued at $23,368,000 after purchasing an additional 1,045,305 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of research reports. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Finally, Piper Sandler lifted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Up 0.8 %

Shares of Teva Pharmaceutical Industries stock traded up $0.13 on Thursday, reaching $15.64. 8,097,026 shares of the company's stock were exchanged, compared to its average volume of 9,948,488. The company has a market capitalization of $17.73 billion, a P/E ratio of -10.83, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm's 50-day moving average is $15.13 and its two-hundred day moving average is $17.52.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.